{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:38Z","timestamp":1791302498891,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.intimp.2024.112276","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T16:55:41Z","timestamp":1717088141000},"page":"112276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-6076","authenticated-orcid":false,"given":"Yohei","family":"Asano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-3802","authenticated-orcid":false,"given":"Satoru","family":"Demura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112276_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.resinv.2022.10.003","article-title":"Prognostic role of modified Glasgow Prognostic score in elderly patients with non-small cell lung cancer treated with anti-PD-1 antibodies","volume":"61","author":"Tanaka","year":"2023","journal-title":"Respir. Investig."},{"key":"10.1016\/j.intimp.2024.112276_b0010","doi-asserted-by":"crossref","unstructured":"F. Bray J. Ferlay I. Soerjomataram R.L. Siegel L.A. Torre A. Jemal Global cancer statistics, GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 68 2018 2018 394 424 10.3322\/caac.21492.","DOI":"10.3322\/caac.21492"},{"key":"10.1016\/j.intimp.2024.112276_b0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112276_b0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients-Experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.intimp.2024.112276_b0025","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/21645515.2020.1823779","article-title":"Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"17","author":"Huang","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2024.112276_b0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.intimp.2024.112276_b0035","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.112276_b0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"OAK Study Group, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.112276_b0045","doi-asserted-by":"crossref","unstructured":"R.L. Siegel K.D. Miller A. Jemal Cancer statistics, CA Cancer J. Clin. 69 2019 2019 7 34 10.3322\/caac.21551.","DOI":"10.3322\/caac.21551"},{"key":"10.1016\/j.intimp.2024.112276_b0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in Advanced squamous-Cell non-small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112276_b0055","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112276_b0060","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 Investigators, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112276_b0065","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 Investigators, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.112276_b0070","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.21873\/anticanres.14933","article-title":"Complete response of bone metastasis in non-small cell lung cancer with pembrolizumab: two case reports","volume":"41","author":"Asano","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2024.112276_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.871675","article-title":"The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer","volume":"12","author":"Asano","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.112276_b0080","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1002\/cam4.5952","article-title":"Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis","volume":"12","author":"Asano","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2024.112276_b0085","doi-asserted-by":"crossref","first-page":"e17400","DOI":"10.1016\/j.heliyon.2023.e17400","article-title":"Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"9","author":"Xia","year":"2023","journal-title":"Heliyon."},{"key":"10.1016\/j.intimp.2024.112276_b0090","doi-asserted-by":"crossref","first-page":"1148786","DOI":"10.3389\/fonc.2023.1148786","article-title":"Prognostic role of C-reactive protein to albumin ratio in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dai","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.112276_b0095","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.112276_b0100","doi-asserted-by":"crossref","first-page":"1213255","DOI":"10.3389\/fnut.2023.1213255","article-title":"Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors","volume":"10","author":"Yan","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.intimp.2024.112276_b0105","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112276_b0110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2024.112276_b0115","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3389\/fimmu.2018.00374","article-title":"Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112276_b0120","doi-asserted-by":"crossref","first-page":"e004440","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.intimp.2024.112276_b0125","first-page":"e049123","article-title":"Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis, BMJ","volume":"11","author":"Yang","year":"2021","journal-title":"(open)"},{"key":"10.1016\/j.intimp.2024.112276_b0130","article-title":"The predictive potential of the baseline C-reactive protein levels for the efficiency of immune checkpoint inhibitors in cancer patients: A systematic review and meta-analysis","volume":"13","author":"Han","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112276_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106677","article-title":"Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis","volume":"85","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.112276_b0140","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fonc.2020.00654","article-title":"Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs)","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.112276_b0145","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s00432-022-03941-2","article-title":"Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer","volume":"148","author":"Shijubou","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112276_b0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2019.08.006","article-title":"Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors","volume":"136","author":"Shoji","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2024.112276_b0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cam4.4940","article-title":"A comprehensive analysis of Glasgow Prognostic Score (GPS)\/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2024.112276_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112276_b0165","doi-asserted-by":"crossref","unstructured":"Z. Zhang, F. Zhang, F. Yuan, Y. Li, J. Ma, Q. Ou, Z. Liu, B. Yang, L. Wang, H. Tao, S. Zhang, X. Li, X. Zhi, X. Ge, H. Bao, X. Wu, Y. Hu, J. Wang, Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer, Ther. Adv. Med. Oncol. 12 (2020) 1758835920970049. 10.1177\/1758835920970049.","DOI":"10.1177\/1758835920970049"},{"key":"10.1016\/j.intimp.2024.112276_b0170","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.3390\/cancers14215297","article-title":"Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A meta-analysis and systematic review","volume":"14","author":"Guo","year":"2022","journal-title":"Cancers (basel)."},{"key":"10.1016\/j.intimp.2024.112276_b0175","doi-asserted-by":"crossref","first-page":"e004024","DOI":"10.1136\/jitc-2021-004024","article-title":"C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer","volume":"10","author":"Kl\u00fcmper","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.intimp.2024.112276_b0180","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s00432-022-04300-x","article-title":"Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR","volume":"149","author":"Matsuzawa","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112276_b0185","first-page":"1001","article-title":"Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients","volume":"85","author":"Onodera","year":"1984","journal-title":"Nihon Geka Gakkai Zasshi."},{"key":"10.1016\/j.intimp.2024.112276_b0190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/0004563215608875","article-title":"Committee on Common Reference Intervals, Japan Society of Clinical Chemistry, Collaborative derivation of reference intervals for major clinical laboratory tests in Japan","volume":"53","author":"Ichihara","year":"2016","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.intimp.2024.112276_b0195","first-page":"223","article-title":"Systemic inflammation, nutritional status and survival in patients with cancer","volume":"12","author":"McMillan","year":"2009","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care."},{"key":"10.1016\/j.intimp.2024.112276_b0200","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.112276_b0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112276_b0210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.112276_b0215","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0002-9610(80)90246-9","article-title":"Prognostic nutritional index in gastrointestinal surgery","volume":"139","author":"Buzby","year":"1980","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.intimp.2024.112276_b0220","doi-asserted-by":"crossref","first-page":"1219929","DOI":"10.3389\/fimmu.2023.1219929","article-title":"Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112276_b0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3892\/ol.2023.14024","article-title":"Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2024.112276_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.823087","article-title":"Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"9","author":"Ni","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.intimp.2024.112276_b0235","doi-asserted-by":"crossref","unstructured":"M. Wu, Y. Zhu, X. Chen, X. Wang, X. Lin, X. Yan, P. Mo, Y. Ye, Y. Zeng, Y. Yang, Z. Fu, Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study, J. Gastrointest. Oncol. 14 (2023) 54\u201363. 10.21037\/jgo-23-48.","DOI":"10.21037\/jgo-23-48"},{"key":"10.1016\/j.intimp.2024.112276_b0240","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112276_b0245","first-page":"1291","article-title":"Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer, Thorac","volume":"9","author":"Takeda","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2024.112276_b0250","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3390\/cancers12082319","article-title":"C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study","volume":"12","author":"Riedl","year":"2020","journal-title":"Cancers (basel)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924007963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:45:03Z","timestamp":1791301503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924007963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"alternative-id":["S1567576924007963"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112276","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112276"}}